<p>Study subjects meeting any of the following criteria will not be included in this study:</p>

<ul>
	<li>Patients under treatment with trelagliptin for type 2 diabetes at the start of screening.</li>
	<li>Patients with a diagnosis of type 1 diabetes.</li>
	<li>Patients with severe renal impairment or renal failure (e.g., eGFR&nbsp;&lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m2&nbsp;or on dialysis).</li>
	<li>Patients with serious heart disease or a cerebrovascular disorder, or a serious pancreatic, blood, or other disease.</li>
	<li>Patients with a history of gastrointestinal resection.</li>
	<li>Patients with a proliferative diabetic retinopathy.</li>
	<li>Patients with malignancy.</li>
	<li>Patients with a history of hypersensitivity or allergy to DPP-4 inhibitors.</li>
	<li>Patients who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.</li>
	<li>Patients who may need to add or discontinue concomitant medication or change the dose during the study period.</li>
	<li>Patients who will require treatment with a prohibited concomitant medication during the study period.</li>
	<li>Patients participating in other clinical studies.</li>
	<li>Patients assessed as ineligible for any other reason by the investigators.</li>
</ul>